 Zacks Investment Research upgraded shares of 89bio NASDAQ:ETNB from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have 26.00 price objective on the stock. According to Zacks, 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the ... 